Riik: Malta
keel: inglise
Allikas: Medicines Authority
SIMETHICONE, ALUMINIUM HYDROXIDE, MAGNESIUM HYDROXIDE
Opella Healthcare France SAS T/A Sanofi 157 avenue Charles de Gaulle, 92200 Neuilly-sur-Seine , France
A02AF02
MAGNESIUM HYDROXIDE 200 mg SIMETHICONE 25 mg ALUMINIUM HYDROXIDE 175 mg
ORAL SUSPENSION
MAGNESIUM HYDROXIDE 200 mg SIMETHICONE 25 mg ALUMINIUM HYDROXIDE 175 mg
OTC
DRUGS FOR ACID RELATED DISORDERS
Authorised
2005-11-04
MAALOX® PLUS 200MG/175MG/25MG PER 5ML ORAL SUSPENSION _magnesium hydroxide _ _aluminium hydroxide _ _simethicone _ READ ALL OF THIS LEAFLET CAREFULLY BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU This medicine is available without prescription. However, you still need to use Maalox Plus Oral Suspension carefully to get the best results from it. • Keep this leaflet. You may need to read it again • Ask your pharmacist if you need more information or advice • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. • You must talk to a doctor if you do not feel better or if you feel worse after taking this medicine. IN THIS LEAFLET: 1. What Maalox Plus Oral Suspension is and what it is used for 2. What you need to know before you take Maalox Plus Oral Suspension 3. How to take Maalox Plus Oral Suspension 4. Possible side effects 5. How to store Maalox Plus Oral Suspension 6. Contents of the pack and other information 1. WHAT MAALOX PLUS ORAL SUSPENSION IS AND WHAT IT IS USED FOR Maalox Plus Oral Suspension contains three different medicines: • The first two medicines are called magnesium hydroxide and aluminium hydroxide. They belong to a group of medicines called antacids. • The other medicines is called simeticone. It belongs to a group of medicines called anti-foaming agents. Maalox Plus Oral Suspension is used for: • The relief of indigestion (dyspepsia) • Heartburn • Wind (flatulence) Maalox Plus Oral Suspension works by lowering the amount of acid in your stomach. The anti- foaming agents in Maalox Plus Oral Suspension helps to remove gas from your stomach. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE MAALOX PLUS ORAL SUSPENSION DO NOT TAKE MAALOX PLUS ORAL SUSPENSION IF: • You are allergic (hypersensitive) to magnesium hydroxide, aluminium hydroxide, simeticone or any of the other ingredients in Maalox Plus Oral Suspension (see Section 6: Contents of the pack and other information). Signs of an allergic reaction in Lugege kogu dokumenti
Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Maalox Plus 200mg/175mg/25mg Oral Suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5ml of the suspension contains: 200mg of Magnesium Hydroxide (as Magnesium Hydroxide Paste). 175mg of Aluminium Hydroxide (as Aluminium Hydroxide Gel) 25mg of Simeticone Excipients: Each 5ml also contains 224.85mg sorbitol (E420), 1.66mg sodium, 3.667mg ethanol, 3ppm sulphur dioxide (E220). For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Oral suspension. A white lemon flavoured oral suspension. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS In the treatment of heartburn, indigestion, flatulence and dysepsia. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The route of administration is oral. Recommended Dosage _Adults:_ One to Two x 5ml spoonfuls four times a day (after meals and at bedtime) or as required. Children: Not recommended 4.3 CONTRA-INDICATIONS Use in severely debilitated patients or in those suffering from kidney failure. Use in patients who are hypersensitive to the active ingredients or to any of the excipients. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Page 2 of 5 Aluminium hydroxide may cause constipation and magnesium salts overdose may cause hypomotility of the bowel; large doses of this product may trigger or aggravate intestinal obstruction and ileus in patients at higher risk such as those with renal impairment, infants less than 2 years, or the elderly. Aluminium hydroxide is not well absorbed from the gastrointestinal tract, and systemic effects are therefore rare in patients with normal renal function. However, excessive doses or long-term use, or even normal doses in patients with low-phosphorus diets or in infants less than 2 years, may lead to phosphate depletion (due to aluminium-phosphate binding) accompanied by increased bone resorption and hypercalciuria with the risk of osteomalacia. Medical advice is recommended in case of long-term use or in patients at risk of phosphate depletion. Ma Lugege kogu dokumenti